37
Participants
Start Date
December 6, 2012
Primary Completion Date
April 27, 2016
Study Completion Date
August 3, 2016
Azacitidine
Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone.
Lenalidomide
Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28.
Off Therapy
2 weeks off therapy, then begin sequence again for 12 weeks.
University of Colorado Cancer Center, Aurora
Collaborators (1)
Celgene
INDUSTRY
University of Colorado, Denver
OTHER